{
  "PMC": "7849956",
  "DOI": "10.1007/s12275-021-0617-7",
  "PMID": "33527314",
  "PMCID": "PMC7849956",
  "title": "Raloxifene as a treatment option for viral infections.",
  "year": 2021,
  "source_url": "https://europepmc.org/article/PMC/PMC7849956",
  "source": "MED",
  "abstract_text": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene's mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections.",
  "full_text": "pmc J Microbiol J Microbiol Journal of Microbiology (Seoul, Korea) 1225-8873 1976-3794 The Microbiological Society of Korea Seoul 7849956 33527314 617 10.1007/s12275-021-0617-7 Minireview Raloxifene as a treatment option for viral infections Hong Subin 1 Chang JuOae 1 Jeong Kwiwan assylum@gbsa.or.kr 2 Lee Wonsik wonsik.lee@skku.edu 1 1 grid.264381.a 0000 0001 2181 989X School of Pharmacy, Sungkyunkwan University, Suwon, 16419 Republic of Korea 2 Bio-center, Gyeonggido Business & Science Accelerator, Suwon, 16229 Republic of Korea 1 2 2021 2021 59 2 124 131 25 11 2020 28 12 2020 28 12 2020 © The Microbiological Society of Korea 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene’s mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections. Keywords raloxifene drug repositioning COVID-19 SARS-CoV-2 SERM estrogen receptor issue-copyright-statement © The Microbiological Society of Korea and Springer Nature B.V. 2021 Conflict of Interest We have no conflicts of interest to report. This work has been supported by Korea Disease Control and Prevention Agency (KCDC 2020-ER5329-00). References Beral V Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 2003 362 419 427 10.1016/S0140-6736(03)14596-5 12927427 Bryant HU Glasebrook AL Yang NN Sato M A pharmacological review of raloxifene J. Bone Miner. Metab. 1996 14 1 9 10.1007/BF01771666 Brzozowski AM Pike AC Dauter Z Hubbard RE Bonn T Engström O Öhman L Greene GL Gustafsson JA Carlquist M Molecular basis of agonism and antagonism in the oestrogen receptor Nature 1997 389 753 758 10.1038/39645 9338790 Cappuccio FP Siani A Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint Nutr. Metab. Cardiovasc. Dis. 2020 30 1227 1235 10.1016/j.numecd.2020.05.013 32595085 Clemett D Spencer CM Raloxifene: a review of its use in postmenopausal osteoporosis Drugs 2000 60 379 411 10.2165/00003495-200060020-00013 10983739 Coccolini F Sartelli M Kluger Y Pikoulis E Karamagioli E Moore EE Biffl WL Peitzman A Hecker A Chirica M COVID-19 the showdown for mass casualty preparedness and management: the Cassandra Syndrome World J. Emerg. Surg. 2020 15 26 10.1186/s13017-020-00304-5 32272957 Collaborative Group on Hormonal Factors in Breast Cancer Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence Lancet 2019 394 1159 1168 10.1016/S0140-6736(19)31709-X 31474332 Cummings SR Eckert S Krueger KA Grady D Powles TJ Cauley JA Norton L Nickelsen T Bjarnason NH Morrow M The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial JAMA 1999 281 2189 2197 10.1001/jama.281.23.2189 10376571 Dariya B Nagaraju GP Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients Cytokine Growth Factor Rev. 2020 53 43 52 10.1016/j.cytogfr.2020.05.001 32409230 Delmas PD Bjarnason NH Mitlak BH Ravoux AC Shah AS Huster WJ Draper M Christiansen C Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 1997 337 1641 1647 10.1056/NEJM199712043372301 9385122 Delmas PD Genant HK Crans GG Stock JL Wong M Siris E Adachi JD Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial Bone 2003 33 522 532 10.1016/S8756-3282(03)00241-2 14555255 DeMichele A Troxel AB Berlin JA Weber AL Bunin GR Turzo E Schinnar R Burgh D Berlin M Rubin SC Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study J. Clin. Oncol. 2008 26 4151 4159 10.1200/JCO.2007.14.0921 18757329 Di Martino V Lebray P Myers RP Pannier E Paradis V Charlotte F Moussalli J Thabut D Buffet C Poynard T Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure Hepatology 2004 40 1426 1433 10.1002/hep.20463 15565616 Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 1999 282 637 645 10.1001/jama.282.7.637 10517716 Evans GL Bryant HU Magee DE Turner RT Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia Endocrinology 1996 137 4139 4144 10.1210/endo.137.10.8828469 8828469 Fan H Du X Zhang J Zheng H Lu X Wu Q Li H Wang H Shi Y Gao G Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium Sci. Rep. 2017 7 41226 10.1038/srep41226 28117364 Fugère P Scheele WH Shah A Strack TR Glant MD Jolly E Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in post-menopausal women Am. J. Obstet. Gynecol. 2000 182 568 574 10.1067/mob.2000.104768 10739509 Furusyo N Ogawa E Sudoh M Murata M Ihara T Hayashi T Ikezaki H Hiramine S Mukae H Toyoda K Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial J. Hepatol. 2012 57 1186 1192 10.1016/j.jhep.2012.08.003 22889955 Gavriatopoulou M Korompoki E Fotiou D Ntanasis-Stathopoulos I Psaltopoulou T Kastritis E Terpos E Dimopoulos MA Organ-specific manifestations of COVID-19 infection Clin. Exp. Med. 2020 20 493 506 10.1007/s10238-020-00648-x 32720223 Gianni W Ricci A Gazzaniga P Brama M Pietropaolo M Votano S Patanè F Aglianò AM Spera G Marigliano V Raloxifene modulates interleukin-6 and tumor necrosis factor- α synthesis in vivo: results from a pilot clinical study J. Clin. Endocrinol. Metab. 2004 89 6097 6099 10.1210/jc.2004-0795 15579764 Goldstein SR Scheele WH Rajagopalan SK Wilkie JL Walsh BW Parsons AK A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium Obstet. Gynecol. 2000 95 95 103 10636510 Gottardis MM Jordan VC Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model Cancer Res. 1987 47 4020 4024 3607747 Haldosén LA Zhao C Dahlman-Wright K Estrogen receptor beta in breast cancer Mol. Cell. Endocrinol. 2014 382 665 672 10.1016/j.mce.2013.08.005 23954741 Heldring N Pike A Andersson S Matthews J Cheng G Hartman J Tujague M Ström A Treuter E Warner M Estrogen receptors: how do they signal and what are their targets Physiol. Rev. 2007 87 905 931 10.1152/physrev.00026.2006 17615392 Hoenen T Groseth A Feldmann H Therapeutic strategies to target the Ebola virus life cycle Nat. Rev. Microbiol. 2019 17 593 606 10.1038/s41579-019-0233-2 31341272 Jones, J.E., Le Sage, V., and Lakdawala, S.S. 2020. Viral and host heterogeneity and their effects on the viral life cycle. Nat. Rev. Microbiol. 10.1038/s41579-020-00449-9. Jordan VC Tamoxifen: catalyst for the change to targeted therapy Eur. J. Cancer 2008 44 30 38 10.1016/j.ejca.2007.11.002 18068350 Jordan RE Adab P Who is most likely to be infected with SARS-CoV-2? Lancet Infect. Dis. 2020 20 995 996 10.1016/S1473-3099(20)30395-9 32422197 Kesharwani D Paliwal R Satapathy T Das Paul S Rheumatiod arthritis: an updated overview of latest therapy and drug delivery J. Pharmacopuncture 2019 22 210 224 10.3831/KPI.2019.22.029 31970018 Kumar V Chambon P The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer Cell 1988 55 145 156 10.1016/0092-8674(88)90017-7 3167974 Kumar R Zakharov MN Khan SH Miki R Jang H Toraldo G Singh R Bhasin S Jasuja R The dynamic structure of the estrogen receptor J. Amino Acids 2011 2011 812540 10.4061/2011/812540 22312471 Ledford H Coronavirus breakthrough: Dexamethasone is first drug shown to save lives Nature 2020 582 469 10.1038/d41586-020-01824-5 32546811 Levenson AS Wolf DM Catherino WH Takei H Jordan VC Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen Breast Cancer 1998 5 99 106 10.1007/BF02966681 11091634 Lippman SM Brown PH Tamoxifen prevention of breast cancer: an instance of the fingerpost J. Natl. Cancer Inst. 1999 91 1809 1819 10.1093/jnci/91.21.1809 10547388 Lo MK Albariño CG Perry JK Chang S Tchesnokov EP Guerrero L Chakrabarti A Shrivastava-Ranjan P Chatterjee P McMullan LK Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases Proc. Natl. Acad. Sci. USA 2020 117 26946 26954 10.1073/pnas.2012294117 33028676 MacGregor JI Jordan VC Basic guide to the mechanisms of antiestrogen action Pharmacol. Rev. 1998 50 151 196 9647865 Mahase E Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy BMJ 2020 371 m4120 10.1136/bmj.m4120 Matthay MA Wick KD Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome J. Clin. Invest. 2020 130 6218 6221 10.1172/JCI143331 32976118 Myers L Balakrishnan S Reddy S Gholamrezanezhad A Coronavirus outbreak: is radiology ready? Mass casualty incident planning J. Am. Coll. Radiol. 2020 17 724 729 10.1016/j.jacr.2020.03.025 32304643 Nelson HD Menopause Lancet 2008 371 760 770 10.1016/S0140-6736(08)60346-3 18313505 Omoto Y Iwase H Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects Cancer Sci. 2015 106 337 343 10.1111/cas.12613 25611678 Ozma MA Maroufi P Khodadadi E Kose S Esposito I Ganbarov K Dao S Esposito S Dal T Zeinalzadeh E Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period Infez. Med. 2020 28 153 165 32275257 Pardo J Shukla AM Chamarthi G Gupte A The journey of remdesivir: from Ebola to COVID-19 Drugs Context 2020 9 2020 4 10.7573/dic.2020-4-14 32547625 Patel HK Bihani T Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment Pharmacol. Ther. 2018 186 1 24 10.1016/j.pharmthera.2017.12.012 29289555 Patel SK Saikumar G Rana J Dhama J Yatoo MI Tiwari R Rodriguez-Morales AJ Dhama K Dexamethasone: A boon for critically ill COVID-19 patients? Travel Med. Infect. Dis. 2020 37 101844 10.1016/j.tmaid.2020.101844 32791213 Pawlak M Lefebvre P Staels B General molecular biology and architecture of nuclear receptors Curr. Top. Med. Chem. 2012 12 486 504 10.2174/156802612799436641 22242852 Pearce ST Jordan VC The biological role of estrogen receptors a and β in cancer Crit. Rev. Oncol. Hematol. 2004 50 3 22 10.1016/j.critrevonc.2003.09.003 15094156 Peretz J Hall OJ Klein SL Klein SL Roberts CW Sex differences in influenza virus infection, vaccination, and therapies Sex and Gender Differences in Infection and Treatments for Infectious Diseases 2015 Cham, Switzerland Springer International Publishing 183 210 Peretz J Pekosz A Lane AP Klein SL Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors Am. J. Physiol. Lung Cell. Mol. Physiol. 2016 310 L415 L425 10.1152/ajplung.00398.2015 26684252 Perou CM Sørlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Molecular portraits of human breast tumours Nature 2000 406 747 752 10.1038/35021093 10963602 Prasad A Prasad M Single virus targeting multiple organs: what we know and where we are heading? Front. Med. 2020 7 370 10.3389/fmed.2020.00370 Ragia G Manolopoulos VG Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies Eur. J. Clin. Pharmacol. 2020 76 1623 1630 10.1007/s00228-020-02963-4 32696234 Rey JRC Cervino EV Rentero ML Crespo EC Álvaro AO Casillas M Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice Open Orthop. J. 2009 3 14 21 10.2174/1874325000903010014 19516920 Rhen T Cidlowski JA Antiinflammatory action of glucocorticoids-new mechanisms for old drugs N. Engl. J. Med. 2005 353 1711 1723 10.1056/NEJMra050541 16236742 Riggs BL The mechanisms of estrogen regulation of bone resorption J. Clin. Invest. 2000 106 1203 1204 10.1172/JCI11468 11086020 Riggs BL Hartmann LC Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice N. Engl. J. Med. 2003 348 618 629 10.1056/NEJMra022219 12584371 Shimizu I Impact of oestrogens on the progression of liver disease Liver Int. 2003 23 63 69 10.1034/j.1600-0676.2003.00811.x 12640729 Smetana K Jr. Rosel D BrÁbek J Raloxifene and bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality In Vivo 2020 34 3027 3028 10.21873/invivo.12135 32871847 Straub RH The complex role of estrogens in inflammation Endocr. Rev. 2007 28 521 574 10.1210/er.2007-0001 17640948 Takeda M Ikeda M Mori K Yano M Ariumi Y Dansako H Wakita T Kato N Raloxifene inhibits hepatitis C virus infection and replication FEBS Open Bio. 2012 2 279 283 10.1016/j.fob.2012.08.003 23650611 Turner CH Sato M Bryant HU Raloxifene preserves bone strength and bone mass in ovariectomized rats Endocrinology 1994 135 2001 2005 10.1210/endo.135.5.7956922 7956922 Tzukerman MT Esty A Santiso-Mere D Danielian P Parker MG Stein RB Pike JW McDonnell DP Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions Mol. Endocrinol. 1994 8 21 30 8152428 Vogel VG Costantino JP Wickerham DL Cronin WM Cecchini RS Atkins JN Bevers TB Fehrenbacher L Pajon ER Jr. Wade JL 3rd Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) p-2 trial JAMA 2006 295 2727 2741 10.1001/jama.295.23.joc60074 16754727 WHO, World Health Organization. 2020. COVID-19 weekly epidemiological update, 17 November 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update—-17-november-2020 . Yang NN Venugopalan M Hardikar S Glasebrook A Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene Science 1996 273 1222 1225 10.1126/science.273.5279.1222 8703055 Yoon YS Jang Y Hoenen T Shin H Lee Y Kim M Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles BMB Rep. 2020 53 166 171 10.5483/BMBRep.2020.53.3.175 31964466 Zhang Y Geng X Tan Y Li Q Xu C Xu J Hao L Zeng Z Luo X Liu F New understanding of the damage of SARS-CoV-2 infection outside the respiratory system Biomed. Pharmacother. 2020 127 110195 10.1016/j.biopha.2020.110195 32361161",
  "plain_text": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene’s mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections."
}
